Chemotherapy

Number of patients, n (%)

IV Carboplatin + IV Paclitaxel

58 (16.6%)

IV/IP Cisplatin + Paclitaxel

52 (14.9%)

Single-agent Carboplatin

50 (14.4%)

Single-agent Cisplatin

28 (8%)

Cisplatin + 5-fluorouracil

19 (5.5%)

Liposomal doxorubicin

17 (4.9%)

Carboplatin + liposomal doxorubicin

15 (4.3%)

Paclitaxel + bevacizumab

15 (4.3%)

EMA-CO

13 (3.7%)

Single-agent paclitaxel

13 (3.7%)

Gemcitabine

9 (2.6%)

Carboplatin + Gemcitabine

6 (1.7%)

Other, including trials

53 (15.2%)